Some genetic diseases can now be cured, and the number is growing. As of 2025, the FDA has approved gene therapies that offer one-time, potentially permanent treatments for conditions like sickle cell disease, spinal muscular atrophy, an inherited form of blindness, hemophilia B, and beta-thalassemia. These aren’t just better treatments. They fix or work around the underlying genetic problem itself. But the picture is more complicated than a simple yes: cures exist only for a narrow slice of the thousands of known genetic conditions, and whether they work for a given disease depends heavily on the type of genetic error involved.
Why Some Genetic Diseases Are Easier to Cure
The genetic diseases with approved cures share a common trait: they’re caused by a single faulty gene. Sickle cell disease, for example, results from one specific mutation in the gene that codes for hemoglobin. Spinal muscular atrophy stems from a missing or defective copy of a single gene needed for motor nerve survival. When a disease traces back to one broken instruction in your DNA, scientists can design a therapy that either delivers a working copy of that gene or edits the mistake directly.
Diseases caused by many genes acting together are a different story entirely. Conditions like heart disease, type 2 diabetes, most cancers, and schizophrenia involve dozens or hundreds of genetic variants, each contributing a small amount of risk, and they’re heavily influenced by environment and lifestyle. There’s no single edit that fixes the problem. These polygenic conditions remain far beyond the reach of current gene therapy, and that’s unlikely to change soon.
How Gene Therapy Actually Works
Gene therapies fall into two broad categories based on where the work happens. In one approach, doctors remove cells from your body (usually blood stem cells), modify them in a lab, and infuse them back. This is how the sickle cell disease treatments work. In the other approach, the therapy is delivered directly into your body, typically through an engineered virus that carries a working gene to the right tissue. The treatment for inherited blindness, for instance, is injected directly into the eye.
The most well-known editing tool is CRISPR-Cas9, which works like molecular scissors. A small piece of guide RNA directs the Cas9 protein to a precise location in your DNA, where it cuts both strands. The cell then repairs the break, and scientists can harness that repair process to correct a mutation, delete a problematic sequence, or insert new genetic material. For sickle cell disease, one strategy uses CRISPR to disable a gene that suppresses fetal hemoglobin, a form of hemoglobin that works normally and can compensate for the defective adult version. With that suppressor gene knocked out, the body starts producing fetal hemoglobin again, preventing red blood cells from sickling.
Newer tools called base editors and prime editors refine this process further. Standard CRISPR cuts through both DNA strands, which can sometimes cause unwanted insertions or deletions. Base editors chemically convert one DNA letter to another without cutting, making them more precise for correcting single-letter mutations. Prime editors go even further, handling all twelve possible types of letter swaps plus small insertions and deletions. In principle, prime editing could correct up to 89% of known disease-causing genetic variants. These tools also work in cells that aren’t actively dividing, which opens the door to treating tissues like the brain and heart that standard CRISPR struggles to reach.
Diseases With Approved Cures
The list of genetic diseases with FDA-approved gene therapies is still short, but the results for patients on that list can be dramatic.
For a rare inherited retinal disease that causes progressive blindness, a gene therapy called Luxturna delivers a working copy of the defective gene directly to cells in the retina. In a phase 3 trial, 65% of treated patients achieved the maximum possible improvement on a functional vision test, navigating a mobility course at light levels as low as 1 lux (roughly equivalent to a moonlit night). Untreated patients showed essentially no change. Light sensitivity improved by more than 100-fold within the first month and remained stable over a year.
For spinal muscular atrophy type 1, the most severe form, untreated infants face a grim prognosis: only 26% survive without permanent ventilation by 14 months of age. With gene therapy, that number jumps to 91%. The treatment delivers a functional copy of the missing gene through a one-time intravenous infusion. Timing matters enormously here. Children treated early, before significant nerve damage occurs, see the best outcomes. Those treated at more advanced stages may show modest improvements in motor scores but often don’t achieve new milestones like sitting or walking independently.
For hemophilia B, a condition where the blood doesn’t clot properly, gene therapy reduced bleeding episodes requiring treatment by 77% compared to the standard approach of regular clotting factor infusions. That improvement held steady through three years of follow-up data. For many patients, this means going from weekly or biweekly infusions to little or no treatment at all.
Two gene therapies for sickle cell disease, Casgevy and Lyfgenia, were approved in late 2023. Both aim to be one-time cures. Casgevy uses CRISPR-based editing to reactivate fetal hemoglobin production, while Lyfgenia uses a viral vector to deliver a modified hemoglobin gene.
How Long Do These Cures Last?
This is the question that complicates the word “cure.” Gene therapies are designed to create permanent or very long-lasting changes, but many of these treatments are only a few years old. We don’t yet have decades of data confirming lifelong durability for most of them. The FDA requires manufacturers to monitor patients for up to fifteen years after treatment with genome editing products or viral vectors that integrate into DNA, and up to five years for some other delivery methods.
Early evidence is encouraging. Some of the first children treated with gene therapy for severe combined immunodeficiency (the “bubble boy” disease) in studies conducted in France and the United Kingdom still have functioning immune systems years later, with no transfusions needed. But those same early trials also revealed a serious risk: years after treatment, a significant number of children developed a leukemia-like cancer caused by the viral vector inserting itself near a cancer-promoting gene. Most did not develop cancer, but the fact that some did underscores why long-term follow-up matters.
Modern gene therapies use safer viral vectors and more precise editing tools, significantly reducing these risks. Still, the honest answer is that “cure” in this context means the disease is corrected at the genetic level and remains corrected for as long as we’ve been able to observe, which for most current therapies is five to ten years.
Cost as a Barrier
Even when a cure exists, accessing it is another challenge. Gene therapies are among the most expensive treatments in medicine. The two sickle cell disease gene therapies each carry list prices above $2 million. These are one-time treatments, and advocates argue the cost is justified when compared to a lifetime of emergency care, hospitalizations, and chronic pain management. But paying $2 million up front is a fundamentally different challenge for patients and insurance systems than spreading costs over decades.
The treatment process itself is also demanding. For blood-based gene therapies like the sickle cell treatments, patients typically undergo chemotherapy to destroy their existing bone marrow before receiving the modified cells. This process takes weeks of hospitalization and carries its own serious risks, including infection and infertility. It’s a far cry from taking a pill.
What Remains Out of Reach
The vast majority of genetic diseases still have no cure. Over 7,000 rare diseases have been identified, most of them genetic, and approved gene therapies address fewer than a dozen. Conditions caused by multiple genes, diseases affecting hard-to-reach tissues like the brain, and disorders where damage has already occurred before diagnosis all present obstacles that current technology hasn’t overcome.
Some conditions also involve genes too large to fit inside the viral vectors used to deliver gene therapy. Base editing and prime editing may help with this problem, since they correct mutations in place rather than delivering an entire replacement gene. Autosomal dominant diseases, where you only need one bad copy of a gene to be affected, require silencing the defective gene rather than just adding a working one, which adds another layer of complexity that newer editing tools are better equipped to handle.
The trajectory is clear: more genetic diseases will become curable as editing tools improve, delivery methods get safer, and manufacturing costs come down. But for now, the answer to “can genetic diseases be cured?” is a qualified yes, limited to a small and specific set of single-gene conditions, with the understanding that “cured” still carries some uncertainty about what happens twenty or thirty years from now.